Results 261 to 270 of about 590,153 (303)

Application of humanized mice in the safety experiments of antibody drugs

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The graphical abstract of this review highlights the critical role of humanized mice in the safety evaluation of antibody drugs. First, the inherent immunogenicity of antibody drugs can lead to the production of antidrug antibodies and hypersensitivity reactions on repeated administration.
Zhimin Sun   +9 more
wiley   +1 more source

Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics

open access: yesAnnals of Neurology, EarlyView.
Objectives Rapid advances in transcriptomics have driven efforts to identify deregulated pathways in multiple sclerosis (MS) tissues, though many detected differentially expressed genes are likely false positives, with only a small fraction reflecting actual pathological events. Robust, integrative methods are essential for accurately understanding the
Gianmarco Abbadessa   +11 more
wiley   +1 more source

The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria

open access: yesAngewandte Chemie, EarlyView.
AZD0156, an ATM kinase inhibitor in clinical development, shows promising multistage antiplasmodial activity by targeting Plasmodium falciparum phosphatidylinositol 4‐kinase (PfPI4Kβ). With an improved specificity profile relative to other PfPI4Kβ inhibitors and moderate efficacy in a P.
John G. Woodland   +33 more
wiley   +2 more sources

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

open access: yesAnnals of Neurology, EarlyView.
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr.   +2 more
wiley   +1 more source

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

open access: yesAngewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker   +3 more
wiley   +2 more sources

Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies

open access: yesAnnals of Neurology, EarlyView.
Autosomal recessive cerebellar ataxias are disabling neurodegenerative genetic conditions affecting balance and coordination. Advancements in genomic testing have improved diagnosis, leading to a new focus on the development of targeted precision therapeutics addressing cellular, biochemical, and genetic disease mechanisms with a resulting emphasis on ...
Brent L. Fogel   +10 more
wiley   +1 more source

Multiple and Alternative Sites Make Tau Protein an Adaptable Sticky Surface for the SH3 Domain of Fyn Kinase

open access: yesAngewandte Chemie, EarlyView.
An NMR‐based study, combined with computational, calorimetric and in‐cell FRET methods, sheds light on the complex recognition mechanism between the intrinsically disordered protein Tau and the SH3 domain of Fyn kinase, highlighting how the multiple binding sites present in Tau make the protein an adaptable recognition surface that can function even ...
Roberto Tira   +8 more
wiley   +2 more sources

Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database

open access: yes
American Journal of Hematology, EarlyView.
Fabio Stagno   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy